The Appendiceal Cancer Treatment Market is a highly specialized segment within the broader gastrointestinal oncology landscape, shaped by the rarity of the disease, the diversity of tumor subtypes, and the need for individualized treatment planning. Appendiceal cancers include low-grade mucinous neoplasms, adenocarcinomas, goblet cell tumors, and neuroendocrine tumors, and treatment pathways vary significantly based on histology, grade, tumor location, and extent of spread. Key applications of treatment include localized tumor removal, regional disease control, management of peritoneal dissemination, post-surgical recurrence reduction, and systemic management of advanced or aggressive disease. The principal end-use settings are tertiary hospitals, surgical oncology centers, gastrointestinal cancer programs, and specialized referral institutions with expertise in cytoreductive surgery and intraperitoneal treatment. Recent trends indicate a stronger shift toward pathology-driven care, earlier referral to expert centers, and broader use of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for selected patients with abdominal spread. At the same time, conventional surgery remains the foundation of care for many localized tumors, while chemotherapy, targeted therapy, immunotherapy, and surveillance strategies are being used more selectively depending on disease biology and resectability.